Research use onlyFor laboratory and research purposes only — not for human consumption, medical, veterinary or diagnostic use.

PeptideStacks
receptor

GLP-1 receptor

also: GLP-1R, Glucagon-like peptide-1 receptor, GLP1R

Glucagon-like peptide-1 receptor, a class B GPCR mediating incretin-driven insulin secretion, appetite suppression, and gastric emptying delay.

The GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor expressed on pancreatic beta cells, the central nervous system, heart, kidney, and gastrointestinal tract. Its endogenous ligand, Glucagon-like peptide-1 (GLP-1), is a 30-amino-acid incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, and GLP-1R activation drives insulin secretion in a glucose-dependent manner while simultaneously suppressing glucagon release and slowing gastric emptying.

Why it matters in peptide research

The GLP-1 receptor has become one of the most therapeutically important targets in modern medicine following the clinical success of receptor agonists in treating type 2 diabetes and obesity. Its glucose-dependent mechanism of insulin stimulation is a critical safety feature: unlike sulfonylureas, GLP-1R agonists only amplify insulin secretion when blood glucose is elevated, dramatically reducing hypoglycemia risk.

Central GLP-1R signaling in the hypothalamus and brainstem reduces appetite and food intake by promoting satiety signaling and dampening reward-driven eating. This central component, combined with peripheral slowing of gastric emptying, produces the sustained caloric restriction that underlies the significant body weight reductions observed with pharmacological GLP-1R agonism. Understanding this dual peripheral-central action is essential for interpreting the clinical and research profiles of GLP-1R-targeting peptides.

Beyond metabolic effects, GLP-1R activation has demonstrated cardioprotective, neuroprotective, and anti-inflammatory properties in preclinical models, opening research avenues beyond diabetes and obesity into areas such as NASH, Alzheimer's disease, and heart failure.

Peptides that act on this

  • Tirzepatide — dual GLP-1R/GIP receptor agonist; superior weight loss and glycemic control compared to GLP-1R mono-agonism; approved for type 2 diabetes and obesity.
  • Retatrutide — triple agonist (GLP-1R, GIP receptor, glucagon receptor); early-phase data show the most pronounced weight loss of any peptide in this class to date.
  • Semaglutide — highly potent selective GLP-1R agonist (Ozempic/Wegovy); the dominant clinical benchmark.
  • Liraglutide — earlier-generation GLP-1R agonist; daily injection required.

Common misconceptions

A prevalent misconception is that GLP-1 receptor agonists are simple "appetite suppressants." Their mechanism is more nuanced: insulin potentiation, glucagon inhibition, gastric emptying delay, central satiety signaling, and direct organ-protective effects all contribute simultaneously. This complexity is why side-effect profiles (particularly nausea and gastrointestinal motility changes) are mechanistically predictable, and titration strategies that ramp dose slowly are the standard clinical approach.

Related glossary entries